A Phase I, Multi-center, Open-label, Study to Investigate the Safety, Tolerability and Pharmacokinetic of SLC-0111 in Subjects With Advanced Solid Tumours

Trial Profile

A Phase I, Multi-center, Open-label, Study to Investigate the Safety, Tolerability and Pharmacokinetic of SLC-0111 in Subjects With Advanced Solid Tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 26 May 2016

At a glance

  • Drugs SLC 0111 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors SignalChem Lifesciences; Welichem Biotech
  • Most Recent Events

    • 13 May 2016 Status changed from recruiting to completed.
    • 08 Dec 2015 Planned number of patients changed from 34 to 24 as reported by ClinicalTrials.gov.
    • 16 Nov 2015 Planned end date changed from 1 Mar 2016 to 1 Apr 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top